About
us
It is
our mission to help individuals worldwide improve
their vision with the use of non-invasive, risk-free
treatment based on an innovative clinically proven
platform technology.
Company Background
NeuroVision, Inc. is a USA Delaware-registered
Company, founded in December 1999. NeuroVision's R&D, Sales
and Marketing, and Operations are conducted by
NeuroVision Pte Ltd, the Company's wholly-owned
Singaporean subsidiary.
Corporate Values
We are aiming to be the world leader in the field
of non-invasive vision improvement. It is our
business to improve the quality of life through
enhancing the quality of vision.
The values we live by to succeed are:
Innovation
We will always strive to be in the scientific
and technological front line, providing our partners
and customers with the cutting-edge technology.
Quality
We believe that our customers, partners and suppliers
deserve and are able to expect the highest standards
from us in all service encounters. We are committed
to providing and being the best.
Open
We are willing to listen to feedback and provide
you with the knowledge you require to make an
informed choice.
Vibrant
We are passionate about your vision. We aim to
provide you with an energetic and dynamic level
of service.
Strategic
Partnerships
The Singapore
Eye Research Institute (SERI) is our primary
research and clinical partner.
The Singapore
National Eye Center (SNEC) is our first commercial
provider of NeuroVision's treatments in Asia,
and our reference center.
Leadership
NeuroVision's CEO is Mr. Nir
Ellenbogen, a senior executive with vast international
management experience in the industry.
NeuroVision’s V.P of R&D is Mr. Coby
Schondorf, bringing a broad experience in
management of research and development of large
scale commercial systems.
NeuroVision management is an experienced team
of accomplished executives, managing an interdisciplinary
team of healthcare professionals, neuroscientists
and computer scientists. Management shares over
50 years of combined corporate and start-up experience.
Financial
Background
NeuroVision is backed by three leading venture
funds:
EDB Investments BioMedical Sciences Investment
Fund - "BMSIF"
Concord
Ventures
BioVeda
Mandarin
Opto-medic
Omega
SPV I, L.P
Board
of Directors
Matty
Karp ,
Chairman, Managing Partner at Concord Ventures
Jeremy
Loh,
Investments Manager at EDBI's Bio*One Investment Fund
Otello
Stampacchia,
Managing Director, Omega Fund
Roger
Durantis,
Senior VP of New Businesses at Essilor International
Nir
Ellenbogen,
CEO of Neurovision
Scientific
Advisory Board (in alphabetical order)
Prof.
Michael Belkin, MD
Professor of Ophthalmology, Director, Ophthalmic
Technologies Laboratory Goldschleger Eye Research
Institute
Tel Aviv University Sheba Medical Center
Daniel
Durrie, MD
Durrie Vision Clinics,
Overland Park, KS, USA
Jack
T. Holladay, MD
Holladay LASIK Institute,
Bellaire, TX, USA
Jay
McDonald, MD
McDonald Eye Associates,
Fayetteville, AR, USA
Dr.
Ian Morgan
Head
Visual Sciences Group, Australia
Prof.
Donald Tan, MD (Chief of SAB)
Medical Director, Singapore National Eye Centre
Chairman, Singapore Eye Research Institute
Head, Dept of Ophthalmology, National University of Singapore
Professional
Advisory Board
Daniel
Durrie, MD
Durrie Vision Clinics,
Overland Park, KS, USA
Richard
L. Lindstrom, MD
Minnesota Eye Consultants
Minneapolis, MN, USA
Jack
Schaffer, OD
Schaffer Eye Center,
Birmingham AL, USA
Peter
Shaw-McMinn, OD
Private Practice & Southern California
College of Optometry,
Fullerton, CA, USA
Kirk
Smick, OD, FAAO
Chairman of Continuing Education for Vision Expo
& AOA
Clayton Eye Center,
Morrow, GA, USA
Bob
Main, FNAO
President, Professional Optical Concepts,
Draper,
UT, USA
Mike
Packard
Former #2 at LensCrafters,
Chairman of Optical
Dynamics,
Cincinnati, OH, USA
Shareef
Mahdavi
President, SM2 Strategic,
Pleasanton, CA, USA
Judy
F. Gordon
ClinReg Consulting Services, Inc.
|
